Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels
- 1 September 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (5) , 1933-1935
- https://doi.org/10.1182/blood-2003-05-1629
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibBlood, 2003
- Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood, 2002
- Differences between in Vivo and in Vitro Sensitivity to Imatinib of Bcr/Abl+ Cells Obtained from Leukemic PatientsBlood Cells, Molecules, and Diseases, 2002
- α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571Blood, 2002
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Role of alpha1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571JNCI Journal of the National Cancer Institute, 2000